XORTX Announces New Clinical Advisory Board Member
CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (
Stay updated with breaking news from Ronald Perrone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (
CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a biopharmaceutical company focused on developing
email article Metformin was both safe and well tolerated in patients with autosomal dominant polycystic kidney disease (ADPKD), the phase II TAME PKD trial found. The parallel-group, randomized trial of 97 participants found no significant increase in gastrointestinal symptoms over 24 months, according to Ronald Perrone, MD, of Tufts Medical Center in Boston, and colleagues. As measured by the Gastrointestinal Symptoms Rating Scale (GSRS), patients on metformin also didn't see any gastrointestinal tolerability issues compared with those on placebo. "Lactic acidosis and hypoglycemia were...